PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Paediatrician Publishers, LLC 2012-08-01
Reeks:Pediatričeskaâ Farmakologiâ
Onderwerpen:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Online toegang:https://www.pedpharma.ru/jour/article/view/302
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items